Annual Secretarial Compliance Report for the year ended 31.03.2026 pursuant to Regulation 24A of SEBI (LODR) Regulations, 2018.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Oxygenta Pharmaceutical Limited has filed its Annual Secretarial Compliance Report for FY 2025-26, prepared by Practicing Company Secretary Aakanksha Dubey & Co. The report confirms that the company has largely complied with all applicable SEBI regulations including LODR, Prohibition of Insider Trading, and Depositories Regulations. No deviations or penalties were recorded under SEBI regulations. However, the report notes that the company's Manufacturing License (No. 10/MD/AP/2013/B/G) was suspended for seven days by the Drugs Control Administration for violations of the Drugs and Cosmetics Act, 1940. The previous year's report contained no observations. All secretarial standards, board policies, website disclosures, and related party transaction procedures were found compliant.
While the company maintained full compliance with SEBI regulations for FY 2025-26, the manufacturing license suspension is a regulatory concern that could impact production operations, though the license remains valid until April 2028. Shareholders should monitor whether this impacts drug supply or regulatory standing.